Insulin as a bridge between type 2 diabetes and alzheimer disease - how anti-diabetics could be a solution for dementia

Frontiers in Endocrinology

Volumn 5, Issue JUL, 2014, Pages

  Sebastião, Inês ^a,b,c   Candeias, Emanuel ^a,c   Santos, Maria S ^a,b,c   de Oliveira, Catarina R ^a,d   Moreira, Paula I ^a,d   Duarte, Ana I ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer disease; Anti type 2 diabetes compounds; Brain; Exendin 4; Incretins glucagon like peptide 1 glucagon like peptide 1 receptor; Insulin insulin receptor signaling; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETOHEXAMIDE; ALBIGLUTIDE; ALOGLIPTIN; BIGUANIDE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; LINAGLIPTIN; LIXISENATIDE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE;

ALZHEIMER DISEASE; BLOOD GLUCOSE MONITORING; DEGENERATIVE DISEASE; DEMENTIA; ENERGY METABOLISM; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

EID: 84905437740     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00110     Document Type: Review

References (145)

1. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther (2011) 33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015
2. Correia SC, Santos RX, Carvalho C, Cardoso S, Candeias E, Santos MS, et al. Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. Brain Res (2012) 1441:64-78. doi:10.1016/j.brainres.2011.12.063
3. Biessels GJ, Deary IJ, Ryan CM. Cognition and diabetes: a lifespan perspective. Lancet Neurol (2008) 7(2):184-90. doi:10.1016/S1474-4422(08)70021-8
4. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care (2004) 27(7):1798-811. doi:10.2337/diacare.27.7.1798
5. Sims-Robinson C, Kim B, Rosko A, Feldman E. How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol (2011) 6:551-9. doi:10.1038/nrneurol.2010.130
6. Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab (2012) 23(3):133-41. doi:10.1016/j.tem.2011.12.004
7. Kitamura T. The role of FOXO1 in ß-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol (2013) 9(10):615-23. doi:10.1038/nrendo.2013.157
8. Jellinger KA. The pathology of "vascular dementia": a critical update. J Alzheimers Dis (2008) 14(1):107-23.
9. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev (2007) 56(2):384-402. doi:10.1016/j.brainresrev.2007.09.001
10. Biessels GJ, Gispen WH. The impact of diabetes on cognition: what can be learned from rodent models? Neurobiol Aging (2005) 26(1):36-41. doi:10.1016/j.neurobiolaging.2005.08.015
11. Roriz-Filho S, Sá-Roriz TM, Rosset I, Camozzato AL, Santos AC, Chaves MLF, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta (2009) 1792(5):432-43. doi:10.1016/j.bbadis.2008.12.003
12. Pasquier F, Boulogne A, Leys D, Fontaine P. Diabetes mellitus and dementia. Diabetes Metab (2006) 32(5 Pt 1):403-14. doi:10.1016/S1262-3636(07)70298-7
13. Kroner Z. The relationship between Alzheimer's disease and diabetes: type 3 diabetes? Altern Med Rev (2009) 14(4):373-9.
14. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res (2012) 2012:384017. doi:10.1155/2012/384017
15. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 53(2):474-81. doi:10.2337/diabetes.53.2.474
16. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 17(lane 2):435-9. doi:10.1038/nature01640
17. Biessels GJ, van der Heide LP, Kamal A, Bleys RL, Gispen WH. Ageing and diabetes: implications for brain function. Eur J Pharmacol (2002) 441(1-2):1-14. doi:10.1016/S0014-2999(02)01486-3
18. Goh S-Y, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 93(4):1143-52. doi:10.1210/jc.2007-1817
19. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta (2010) 1802(1):2-10. doi:10.1016/j.bbadis.2009.10.006
20. Carvalho C, Cardoso S, Correia SC, Santos RX, Santos MS, Baldeiras I, et al. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Diabetes (2012) 61(5):1234-42. doi:10.2337/db11-1186
21. Carvalho C, Machado N, Mota PC, Correia SC, Cardoso S, Santos RX, et al. Type 2 diabetic and Alzheimer's disease mice present similar behavioral, cognitive, and vascular anomalies. J Alzheimers Dis (2013) 35(3):623-35. doi:10.3233/JAD-130005
22. Correia SC, Santos RX, Santos MS, Casadesus G, LaManna JC, Perry G, et al. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr Alzheimer Res (2013) 10(4):406-19. doi:10.2174/1567205011310040006
23. Toro P, Schönknecht P, Schröder J. Type II diabetes in mild cognitive impairment and Alzheimer's disease: results from a prospective population-based study in Germany. J Alzheimers Dis (2009) 16(4):687-91. doi:10.3233/JAD-2009-0981
24. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging (2005) 26(1):65-9. doi:10.1016/j.neurobiolaging.2005.08.021
25. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol (2001) 177(1-2):125-34. doi:10.1016/S0303-7207(01)00455-5
26. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis (2008) 13:241-53.
27. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A (1987) 84(10):3434-8. doi:10.1073/pnas.84.10.3434
28. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl (2007) 72:217-33. doi:10.1007/978-3-211-73574-9_28
29. Freude S, Plum L, Schnitker J, Leeser U, Udelhoven M, Krone W, et al. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes (2005) 54:3343-8. doi:10.2337/diabetes.54.12.3343
30. Biessels GJ, Kamal A, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res (1998) 800(1):125-35.
31. Li Z-G, Zhang W, Grunberger G, Sima AAF. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res (2002) 946(2):221-31. doi:10.1016/S0006-8993(02)02887-1
32. Holroyd CB, Yeung N. Alcohol and error processing. Trends Neurosci (2003) 26(8):402-4. doi:10.1016/S0166-2236(03)00175-9
33. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J (2004) 18(7):902-4. doi:10.1096/fj.03-0978fje
34. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 199(2):265-73. doi:10.1016/j.expneurol.2006.01.018
35. Duarte AI, Santos MS, Oliveira CR, Rego AC. Insulin neuroprotection against oxidative stress in cortical neurons-involvement of uric acid and glutathione antioxidant defenses. Free Radic Biol Med (2005) 39(7):876-89. doi:10.1016/j.freeradbiomed.2005.05.002
36. Duarte AI, Proença T, Oliveira CR, Santos MS, Rego AC. Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes (2006) 55(10):2863-70. doi:10.2337/db06-0030
37. Duarte AI, Santos MS, Seiça R, de Oliveira CR. Insulin affects synaptosomal GABA and glutamate transport under oxidative stress conditions. Brain Res (2003) 977(1):23-30. doi:10.1016/S0006-8993(03)02679-9
38. Duarte AI, Santos MS, Seic R, Oliveira CR. Oxidative stress affects synaptosomal gamma-aminobutyric acid and glutamate transport in diabetic rats. Diabetes (2004) 53:2110-6. doi:10.2337/diabetes.53.8.2110
39. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev (2000) 24(8):855-72. doi:10.1016/S0149-7634(00)00040-3
40. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis (2009) 16(4):741-61. doi:10.3233/JAD-2009-0972
41. Li Z, Zhang W, Sima AAF. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes (2007) 56:1817-24. doi:10.2337/db07-0171.APP
42. Gasparini L, Gouras G, Wang R, Gross R, Beal M, Greengard P, et al. Stimulation of ß-amyloid precursor protein trafficking by insulin reduces intraneuronal ß-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci (2001) 21(8):2561-70.
43. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes-estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27:1047-53. doi:10.2337/diacare.27.10.2569-a
44. Campbell RK, White JR. More choices than ever before: emerging therapies for type 2 diabetes. Diabetes Educ (2013) 34(3):518-34. doi:10.1177/0145721708317870
45. Gavin JR, Stolar MW, Freeman JS, Spellman CW. Improving outcomes in patients with type 2 diabetes mellitus: practical solutions for clinical challenges. J Am Osteopath Assoc (2010) 110(5):2-14.
46. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 35(6):1364-79. doi:10.2337/dc12-0413
47. Morsink LM, Smits MM, Diamant M. Advances in pharmacologic therapies for type 2 diabetes. Curr Atheroscler Rep (2013) 15(2):302. doi:10.1007/s11883-012-0302-8
48. Buse J. Combining insulin and oral agents. Am J Med (2000) 17(108):23-32. doi:10.1016/S0002-9343(00)00339-9
49. Cignarelli A, Giorgino F, Vettor R. Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis. Arch Physiol Biochem (2013) 119(4):139-50. doi:10.3109/13813455.2013.796996
50. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 29(8):1963-72. doi:10.2337/dc06-9912
51. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract (2007) 77(2):280-5. doi:10.1016/j.diabres.2006.11.011
52. Holman R, Paul S, Bethel A, Mathews D, Neil A. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 359:1577-89. doi:10.1056/NEJMoa0806470
53. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am (2005) 34(1):77-98. doi:10.1016/j.ecl.2004.12.002
54. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet (2005) 365(9467):1333-46. doi:10.1016/S0140-6736(05)61032-X
55. Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 9(1):33. doi:10.1186/1741-7015-9-33
56. Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol (2014) 10(3):143-56. doi:10.1038/nrendo.2013.256
57. Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med (1998) 338:867-72. doi:10.1056/NEJM199803263381303
58. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA (2002) 287:360-72.
59. Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X, Ave N. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem (2000) 275(1):223-8. doi:10.1074/jbc.275.1.223
60. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature (2001) 409(6822):860-921. doi:10.1038/35057062
61. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 348:607-14. doi:10.1042/0264-6021:3480607
62. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A (2010) 107(50):21830-5. doi:10.1073/pnas.0912793107
63. Cai Z, Yan L-J, Li K, Quazi SH, Zhao B. Roles of AMP-activated protein kinase in Alzheimer's disease. Neuromolecular Med (2012) 14(1):1-14. doi:10.1007/s12017-012-8173-2
64. Grisouard J, Timper K, Radimerski TM, Frey DM, Peterli R, Kola B, et al. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes. Biochem Pharmacol (2010) 80(11):1736-45. doi:10.1016/j.bcp.2010.08.021
65. Correia S, Carvalho C, Santos MS, Proença T, Nunes E, Duarte AI, et al. Metformin protects the brain against the oxidative imbalance promoted by type 2 diabetes. Med Chem (2008) 4(4):358-64. doi:10.2174/157340608784872299
66. Guigas B, Detaille D, Chauvin C, Batandier C, De Oliveira F, Fontaine E, et al. Metformin inhibits mitochondrial permeability transition and cell death: a pharmacological in vitro study. Biochem J (2004) 382:877-84. doi:10.1042/BJ20040885
67. Jornayvaz FR, Gerald I. Regulation of mitochondrial biogenesis. Essays Biochem (2010) 47:69-84. doi:10.1042/BSE0470069
68. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 108:1167-74. doi:10.1172/JCI200113505
69. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2013) 36(10):2981-7. doi:10.2337/dc13-0229
70. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis (2014) 41(1):61-8. doi:10.3233/JAD-131901
71. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav (2012) 101(4):564-74. doi:10.1016/j.pbb.2012.03.002
72. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology (2011) 60(6):910-20. doi:10.1016/j.neuropharm.2011.01.033
73. Chen Y, Zhou K, Wang R, Liu Y, Kwak Y, Ma T, et al. Antidiabetic drug metformin (glucophage R) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A (2009) 106(10):3907-12. doi:10.1073/pnas.0807991106
74. Li J, McCullough LD. Effects of AMP-activated protein kinase in cerebral ischemia. J Cereb Blood Flow Metab (2010) 30(3):480-92. doi:10.1038/jcbfm.2009.255
75. McCullough LD, Zeng Z, Li H, Landree LE, McFadden J, Ronnett GV. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J Biol Chem (2005) 280(21):20493-502. doi:10.1074/jbc.M409985200
76. Ronnett GV, Ramamurthy S, Kleman AM, Landree LE, Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J Neurochem (2009) 109:17-23. doi:10.1111/j.1471-4159.2009.05916.x
77. Ju T-C, Chen H-M, Lin J-T, Chang C-P, Chang W-C, Kang J-J, et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol (2011) 194(2):209-27. doi:10.1083/jcb.201105010
78. Carvalho C, Correia S, Santos MS, Seiça R, Oliveira CR, Moreira PI. Metformin promotes isolated rat liver mitochondria impairment. Mol Cell Biochem (2008) 308(1-2):75-83. doi:10.1007/s11010-007-9614-3
79. Miralles-Linares F, Puerta-Fernandez S, Bernal-Lopez MR, Tinahones FJ, Andrade RJ, Gomez-Huelgas R. Metformin-induced hepatotoxicity. Diabetes Care (2012) 35(3):e21. doi:10.2337/dc11-2306
80. Bloomgarden ZT. Glycemic control in diabetes: a tale of three studies. Diabetes Care (2008) 31(9):1913-9. doi:10.2337/dc08-zb09
81. Aquilante C. Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther (2010) 8:359-72. doi:10.1586/erc.09.154
82. Kilo C, Miller JP, Williamson JR. The crux of the UGDP: spurious results and biologically inappropriate data analysis. Diabetologia (1980) 18:179-85. doi:10.1007/BF00251913
83. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP, Boyd AE, González G, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science (1995) 268(5209):423-6. doi:10.1126/science.7716547
84. Exalto LG, Whitmer RA, Kappele LJ, Biessels GJ. An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol (2012) 47:858-64. doi:10.1016/j.exger.2012.07.014
85. Hsu C-C, Wahlqvist ML, Lee M-S, Tsai H-N. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis (2011) 24(3):485-93. doi:10.3233/JAD-2011-101524
86. Tafuri S. Troglitazone enhances differentiation, basal glucose uptake and GLUT1 protein levels in 2T3-L1 adipocytes. Endocrinology (1996) 137:4706-12. doi:10.1210/en.137.11.4706
87. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab (2011) 13:221-8. doi:10.1111/j.1463-1326.2010.01349.x
88. Walter H, Lübben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs (2005) 65(1):1-13. doi:10.2165/00003495-200565010-00001
89. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, Defronzo RA, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab (2007) 292:871-83. doi:10.1152/ajpendo.00551.2006
90. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet (2005) 366(9493):1279-89. doi:10.1016/S0140-6736(05)67528-9
91. Juhl CB, Hollingdal M, Pørksen N, Prange A, Lönnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab (2003) 88(8):3794-800. doi:10.1210/jc.2002-021181
92. Leiter LA. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet Med (2005) 22(8):963-72. doi:10.1111/j.1464-5491.2005.01605.x
93. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer's disease: molecular links and clinical implications. Curr Alzheimer Res (2008) 5(5):438-47. doi:10.2174/156720508785908919
94. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone. Am J Geriatr Psychiatry (2005) 13(11):950-8. doi:10.1097/00019442-200511000-00005
95. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics (2008) 5(3):481-9. doi:10.1016/j.nurt.2008.05.003
96. Cardoso S, Carvalho C, Santos R, Correia S, Santos MS, Seiça R, et al. Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. Synapse (2011) 65(6):457-66. doi:10.1002/syn.20863
97. MacLeod K, Hepburn D, Frier B. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med (1993) 10:238-45. doi:10.1111/j.1464-5491.1993.tb00051.x
98. Suh SW, Aoyama K, Matsumori Y, Liu J, Swanson RA. Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment sang. Diabetes (2005) 54:1452-8. doi:10.2337/diabetes.54.5.1452
99. Cardoso S, Santos MS, Seiça R, Moreira PI. Cortical and hippocampal mitochondria bioenergetics and oxidative status during hyperglycemia and/or insulin-induced hypoglycemia. Biochim Biophys Acta (2010) 1802(11):942-51. doi:10.1016/j.bbadis.2010.07.001
100. Cardoso S, Santos RX, Correia SC, Carvalho C, Santos MS, Baldeiras I, et al. Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiol Dis (2013) 49:1-12. doi:10.1016/j.nbd.2012.08.008
101. Craft S, Baker L, Montine T, Minoshima S, Watson S, Claxton A, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol (2011) 69:29-38. doi:10.1001/archneurol.2011.233
102. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab (1964) 24:1076-82. doi:10.1210/jcem-24-10-1076
103. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 368(9548):1696-705. doi:10.1016/S0140-6736(06)69705-5
104. Pérez-Tilve D, González-Matías L, Alvarez-Crespo M, Leiras R, Tovar S, Diéguez C, et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes (2007) 56(1):143-51. doi:10.2337/db05-0996
105. Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta (2013) 1832(4):527-41. doi:10.1016/j.bbadis.2013.01.008
106. Burmeister MA, Ayala J, Drucker DJ, Ayala JE. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am J Physiol Endocrinol Metab (2013) 304(7):677-85. doi:10.1152/ajpendo.00446.2012
107. Gejl M, Egefjord L, Lerche S, Vang K, Bibby BM, Holst JJ, et al. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab (2012) 32(12):2146-52. doi:10.1038/jcbfm.2012.118
108. Hodson DJ, Tarasov AI, Gimeno Brias S, Mitchell RK, Johnston NR, Haghollahi S, et al. Incretin-modulated beta cell energetics in intact islets of Langerhans. Mol Endocrinol (2014) 28(6):860-71. doi:10.1210/me.2014-1038
109. Tsuboi T, Da G, Xavier S, Holz GG, Jouaville LS, Thomas AP, et al. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 ß-cells. Biochem J (2003) 299:287-99. doi:10.1042/BJ20021288
110. Peyot M-L, Gray JP, Lamontagne J, Smith PJS, Holz GG, Madiraju SRM, et al. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PLoS One (2009) 4(7):e6221. doi:10.1371/journal.pone.0006221
111. Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept (2005) 128(2):97-107. doi:10.1016/j.regpep.2004.08.026
112. Tarantola E, Bertone V, Milanesi G, Capelli E, Ferrigno A, Neri D, et al. Dipeptidylpeptidase-IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats. Eur J Histochem (2012) 56(4):e41. doi:10.4081/ejh.2012.e41
113. Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res (2011) 89(4):481-9. doi:10.1002/jnr.22565
114. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A (2000) 97(12):6874-9. doi:10.1073/pnas.120069197
115. Deacon C, Mannucci E, Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab (2012) 14(8):762-7. doi:10.1111/j.1463-1326.2012.01603.x
116. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab (2011) 13:7-18. doi:10.1111/j.1463-1326.2010.01306.x
117. D'Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F, et al. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp Gerontol (2010) 45(3):202-7. doi:10.1016/j.exger.2009.12.004
118. Pintana H, Apaijai N, Chattipakorn N, Chattipakorn SC. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J Endocrinol (2013) 218(1):1-11. doi:10.1530/JOE-12-0521
119. Gallwitz B. Glucagon-like peptide-1 analogues for type 2 diabetes mellitus. Drugs (2011) 71(13):1675-88. doi:10.2165/11592810-000000000-00000
120. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med (2003) 9(9):1173-9. doi:10.1038/nm919
121. McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci (2011) 31(17):6587-94. doi:10.1523/JNEUROSCI.0529-11.2011
122. Han W-N, Hölscher C, Yuan L, Yang W, Wang X-H, Wu M-N, et al. Liraglutide protects against amyloid-ß protein-induced impairment of spatial learning and memory in rats. Neurobiol Aging (2013) 34(2):576-88. doi:10.1016/j.neurobiolaging.2012.04.009
123. Long-Smith CM, Manning S, McClean PL, Coakley MF, O'Halloran DJ, Holscher C, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signaling in parallel with decreasing both amyloid-ß plaque and glial pathology in a mouse model of Alzheimer's disease. Neuromolecular Med (2013) 15(1):102-14. doi:10.1007/s12017-012-8199-5
124. Hunter K, Hölscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci (2012) 13(1):33. doi:10.1186/1471-2202-13-33
125. Gallwitz B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol (2005) 4(6):361-70. doi:10.2165/00024677-200504060-00005
126. Engsbli J, Kleinman W, Singh L, Singh G, Raufman J. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem (1992) 267:7402-5.
127. Chen S, Liu A, An F, Yao W, Gao X. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) (2012) 34(5):1211-24. doi:10.1007/s11357-011-9303-8
128. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 106(4):1285-90. doi:10.1073/pnas.0806720106
129. Robles GI, Singh-Franco D. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther (2009) 3:219-40. doi:10.2147/DDDT.S3321
130. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment. Lancet (2011) 378(9786):182-97. doi:10.1016/S0140-6736(11)60207-9
131. Nielsen LL, Young A, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept (2004) 117(2):77-88. doi:10.1016/j.regpep.2003.10.028
132. Isacson R, Nielsen E, Dannaeus K, Bertilsson G, Patrone C, Zachrisson O, et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur J Pharmacol (2011) 650(1):249-55. doi:10.1016/j.ejphar.2010.10.008
133. Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine (2013) 44(1):47-58. doi:10.1007/s12020-013-9884-3
134. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord (2003) 4:313-8. doi:10.1038/sj.ijo.802206
135. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 132(6):2131-57. doi:10.1053/j.gastro.2007.03.054
136. Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res (2008) 86:326-38. doi:10.1002/jnr
137. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KTY, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther (2002) 300(3):958-66. doi:10.1124/jpet.300.3.958
138. Cryan JF, Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov (2005) 4(9):775-90. doi:10.1038/nrd1825
139. Christensen M, Knop FK, Holst JJ, Vilsboll T. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs (2009) 12(8):503-13.
140. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept (2010) 164(2-3):58-64. doi:10.1016/j.regpep.2010.05.008
141. Sato K, Kameda M, Yasuhara T, Agari T, Baba T, Wang F, et al. Neuroprotective effects of liraglutide for stroke model of rats. Int J Mol Sci (2013) 14(11):21513-24. doi:10.3390/ijms141121513
142. Cai H-Y, Hölscher C, Yue X-H, Zhang S-X, Wang X-H, Qiao F, et al. Lixisenatide rescues spatial memory and synaptic plasticity from amyloid ß protein-induced impairments in rats. Neuroscience (2014). doi:10.1016/j.neuroscience.2014.02.022
143. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab (2012) 14:675-88. doi:10.1111/j.1463-1326.2012.01560.x
144. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab (2009) 11(5):498-505. doi:10.1111/j.1463-1326.2008.00992.x
145. Baggio LL, Huang Q, Brown TJ, Drucker DJA. Recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes (2004) 53:2492-500. doi:10.2337/diabetes.53.9.2492